Back to top

vaccines: Archive

Zacks Equity Research

Biotech Stock Roundup: ITCI Up on Study Data, ZNTL, OVID Down on Updates & More News

Intra-Cellular Therapies (ITCI) and Zentalis Pharmaceuticals, Inc. (ZNTL) are in the spotlight following pipeline and regulatory updates, respectively.

AMGNPositive Net Change MRNAPositive Net Change OVIDPositive Net Change ZNTLPositive Net Change

Zacks Equity Research

Novavax (NVAX) Seeks FDA Nod for Updated COVID-19 Vaccine

Novavax (NVAX) seeks FDA???s approval to update its COVID-19 vaccine for the 2024-2025 fall season against current circulating strains, including KP.2 and KP.3.

SNYPositive Net Change PFEPositive Net Change MRNAPositive Net Change NVAXPositive Net Change

Zacks Equity Research

Moderna's (MRNA) Next-Gen COVID-19 Jab Study Meets Efficacy Goal

Data from a late-stage study shows that Moderna's (MRNA) next-generation COVID-19 vaccine achieved non-inferior vaccine efficacy against COVID-19 when compared with its previously approved bivalent COVID-19 vaccine.

PFEPositive Net Change MRNAPositive Net Change NVAXPositive Net Change BNTXPositive Net Change

Zacks Equity Research

Moderna (MRNA) COVID-Flu Combo Jab Meets Late-Stage Study Goal

Data from a late-stage study shows that Moderna's (MRNA) experimental COVID-19-influenza combination vaccine generates higher immune responses when compared to co-administered licensed flu and COVID vaccines.

PFEPositive Net Change MRNAPositive Net Change NVAXPositive Net Change BNTXPositive Net Change

Sundeep Ganoria

FDA Panel to Consider Updating COVID-19 Jabs for New Virus Strains

An FDA panel meeting is scheduled on Jun 5 to consider if COVID-19 vaccines should be updated to target the WHO-recommended JN.1 variant or the KP.2 variant which is the currently dominating strain in the country.

PFEPositive Net Change MRNAPositive Net Change NVAXPositive Net Change

Zacks Equity Research

Moderna (MRNA) Secures FDA Nod for mRNA-Based RSV Vaccine

The RSV vaccine is Moderna???s (MRNA) second FDA-approved product. Once the vaccine secures the CDC's recommendation, it will be launched in the 2024-2025 respiratory virus season.

GSKPositive Net Change PFEPositive Net Change MRNAPositive Net Change

Zacks Equity Research

Moderna (MRNA) Stock Outperformed Industry YTD: Here's Why

Shares of Moderna (MRNA) are being driven by encouraging pipeline updates and plans for potential product launches.

MRKPositive Net Change MRNAPositive Net Change HRTXNegative Net Change ARQTPositive Net Change

Zacks Equity Research

Pfizer (PFE) Starts Another Cost-Cut Plan to Save $1.5B by 2027

This is the second cost-reduction program undertaken by Pfizer (PFE) in the past year. The first phase of this program is expected to save nearly $1.5 billion by 2027-end.

PFEPositive Net Change HRTXNegative Net Change MRNSPositive Net Change ARQTPositive Net Change